Pharmacotherapy for Pediatric major depression

Rongrong Tao, Graham Emslie, Taryn Mayes

Research output: Contribution to journalArticle

Abstract

Pediatric major depressive disorder (MDD) is a prevalent, chronic, and serious illness that causes short-term and life-long impairment in multiple areas of development and functioning of children and adolescents. The prevalence rates of pediatric MDD are estimated at 2.8% for children and 5.6% for adolescents, based on a recent meta-analysis of 26 studies, with a lifetime prevalence rate of 25%. The response (significant reduction of depressive symptoms) rate to a first antidepressant in randomized-controlled trials (RCTs) of children and adolescents with MDD is about 50% to 60%. About 40% to 50% of adolescents who failed one antidepressant responded to a second antidepressant. As in adult MDD, MDD in children and adolescents has high relapse rates (return of symptoms within the same episode) and recurrence (new episode).

Original languageEnglish (US)
Pages (from-to)192-202
Number of pages11
JournalPsychiatric Annals
Volume40
Issue number4
DOIs
StatePublished - Apr 2010

Fingerprint

Major Depressive Disorder
Depression
Pediatrics
Drug Therapy
Antidepressive Agents
Adolescent Development
Recurrence
Child Development
Meta-Analysis
Chronic Disease
Randomized Controlled Trials

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Pharmacotherapy for Pediatric major depression. / Tao, Rongrong; Emslie, Graham; Mayes, Taryn.

In: Psychiatric Annals, Vol. 40, No. 4, 04.2010, p. 192-202.

Research output: Contribution to journalArticle

Tao, Rongrong ; Emslie, Graham ; Mayes, Taryn. / Pharmacotherapy for Pediatric major depression. In: Psychiatric Annals. 2010 ; Vol. 40, No. 4. pp. 192-202.
@article{7d174a5deeb14522b4eae3c2a6382bd6,
title = "Pharmacotherapy for Pediatric major depression",
abstract = "Pediatric major depressive disorder (MDD) is a prevalent, chronic, and serious illness that causes short-term and life-long impairment in multiple areas of development and functioning of children and adolescents. The prevalence rates of pediatric MDD are estimated at 2.8{\%} for children and 5.6{\%} for adolescents, based on a recent meta-analysis of 26 studies, with a lifetime prevalence rate of 25{\%}. The response (significant reduction of depressive symptoms) rate to a first antidepressant in randomized-controlled trials (RCTs) of children and adolescents with MDD is about 50{\%} to 60{\%}. About 40{\%} to 50{\%} of adolescents who failed one antidepressant responded to a second antidepressant. As in adult MDD, MDD in children and adolescents has high relapse rates (return of symptoms within the same episode) and recurrence (new episode).",
author = "Rongrong Tao and Graham Emslie and Taryn Mayes",
year = "2010",
month = "4",
doi = "10.3928/00485713-20100330-08",
language = "English (US)",
volume = "40",
pages = "192--202",
journal = "Psychiatric Annals",
issn = "0048-5713",
publisher = "Slack Incorporated",
number = "4",

}

TY - JOUR

T1 - Pharmacotherapy for Pediatric major depression

AU - Tao, Rongrong

AU - Emslie, Graham

AU - Mayes, Taryn

PY - 2010/4

Y1 - 2010/4

N2 - Pediatric major depressive disorder (MDD) is a prevalent, chronic, and serious illness that causes short-term and life-long impairment in multiple areas of development and functioning of children and adolescents. The prevalence rates of pediatric MDD are estimated at 2.8% for children and 5.6% for adolescents, based on a recent meta-analysis of 26 studies, with a lifetime prevalence rate of 25%. The response (significant reduction of depressive symptoms) rate to a first antidepressant in randomized-controlled trials (RCTs) of children and adolescents with MDD is about 50% to 60%. About 40% to 50% of adolescents who failed one antidepressant responded to a second antidepressant. As in adult MDD, MDD in children and adolescents has high relapse rates (return of symptoms within the same episode) and recurrence (new episode).

AB - Pediatric major depressive disorder (MDD) is a prevalent, chronic, and serious illness that causes short-term and life-long impairment in multiple areas of development and functioning of children and adolescents. The prevalence rates of pediatric MDD are estimated at 2.8% for children and 5.6% for adolescents, based on a recent meta-analysis of 26 studies, with a lifetime prevalence rate of 25%. The response (significant reduction of depressive symptoms) rate to a first antidepressant in randomized-controlled trials (RCTs) of children and adolescents with MDD is about 50% to 60%. About 40% to 50% of adolescents who failed one antidepressant responded to a second antidepressant. As in adult MDD, MDD in children and adolescents has high relapse rates (return of symptoms within the same episode) and recurrence (new episode).

UR - http://www.scopus.com/inward/record.url?scp=77951748827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951748827&partnerID=8YFLogxK

U2 - 10.3928/00485713-20100330-08

DO - 10.3928/00485713-20100330-08

M3 - Article

AN - SCOPUS:77951748827

VL - 40

SP - 192

EP - 202

JO - Psychiatric Annals

JF - Psychiatric Annals

SN - 0048-5713

IS - 4

ER -